Serum EGFR gene mutation status via second-generation sequencing and clinical features of patients with advanced lung cancer.Objective: To detect the serum epithelial growth factor receptor (EGFR) gene mutation status in patients with lung cancer via second-generation sequencing and to analyze its correlations with the clinical features of patients and its therapeutic effects.  The distribution of the EGFR gene mutation in patients was detected via second-generation sequencing and then patients were divided into mutant-type EGFR group (n=37) and wild-type EGFR group (n=73).  Results: A total of 5 kinds of EGFR gene mutation [19del (45.95%), L858R (43.24%), L861Q (5.41%), S768I (2.70%), and G719X (2.70%)] were detected via second-generation sequencing.  The second-generation sequencing is an important detection method to identify EGFR gene mutation status, which provides an applicable scaffold for the clinical treatment of patients.
second-generation sequencing